BCR and B-cell chronic lymphocytic leukemia: Targeting the proliferative fraction of CLL cells through the inhibition of the signals transmitted by the BcR proved to be a successful therapeutic strategy with remarkable results in both treatment-naïve patients and relapsed/refractory CLL cases [87].